pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
siRNA · news · pharmadog
← back to siRNA
News · siRNA
59
stories
Aug 14, 26
Capricor soars on potential FDA review extension, filing amendments
biospace
Aug 13, 26
Chutes & Ladders—Former Legend CEO lands at K2
fiercebiotech
Aug 11, 26
Silence causes uproar in rare blood cancer space as data sets high bar for competitors
biospace
Aug 11, 26
Epicrispr raises $90M to rewrite treatment of rare muscle disease
fiercebiotech
Aug 10, 26
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
Aug 10, 26
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
endpoints
Aug 10, 26
Silence brings the noise to Takeda with phase 2 blood cancer win
fiercebiotech
Aug 5, 26
STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AI
stat
Aug 5, 26
Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
biospace
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Jul 31, 26
‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spree
fiercebiotech
Jul 29, 26
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
Jul 28, 26
Webinar: Building the Intelligence Engine for Drug Discovery R&D Teams
biospace
Jul 28, 26
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 22, 26
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
biopharma dive
Jul 22, 26
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
biospace
Jun 8, 26
City banks nearly $100M for next-gen RNAi drugs
biopharma dive
Jun 8, 26
City Therapeutics gets $99M to gather data on three RNAi medicines
endpoints
Jun 4, 26
STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher program
stat
Jun 4, 26
STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial
stat
Jun 4, 26
Alnylam, Inceptive ink AI deal potentially worth $2B
biopharma dive
Jun 4, 26
STAT+: AI titans push Congress for DNA safeguards
stat
Jun 4, 26
Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
stat
Jun 3, 26
STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
stat
May 7, 26
Sarepta tumbles as its gene therapy sales decline further
biopharma dive
May 6, 26
GSK goes to China for $1B siRNA deal in Arrowhead's obesity lane
endpoints
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: TriGemX tacks on $94M; AnaCardio adds $71M
fiercebiotech
← prev
page 2 of 2
next →
